Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FeedbackLSE:FDBK EV-to-EBITDA is 0.36 as of Aug. 12, 2026. The stock has 4 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Feedback ranks better than 98.64% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Feedback's enterprise value is £-1.17 Mil.
Feedback's EBITDA for the trailing twelve months (TTM) ended in Nov. 2025 was £-3.24 Mil. Therefore, Feedback's EV-to-EBITDA for today is 0.36.
The historical rank and industry rank for Feedback's EV-to-EBITDA or its related term are showing as below:
LSE:FDBK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.27 Med: -2.59 Max: 1.38
Current: 0.36
During the past 13 years, the highest EV-to-EBITDA of Feedback was 1.38. The lowest was -41.27. And the median was -2.59.
LSE:FDBK's EV-to-EBITDA is ranked better than 98.64% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.9
vs LSE:FDBK: 0.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Feedback's share price for today is £0.0605.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feedback's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 was £-0.164.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Feedback's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FDBK vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Feedback's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feedback EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Feedback's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Feedback's EV-to-EBITDA falls into.
Feedback's current Enterprise Value is £-1.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feedback's EBITDA for the trailing twelve months (TTM) ended in Nov. 2025 was £-3.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feedback (LSE:FDBK) has a EV-to-EBITDA of 0.36 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Feedback. According to the industry distribution chart, Feedback ranks #7 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 1.4%.
Is Feedback's EV-to-EBITDA too high?
Feedback's current EV-to-EBITDA is 0.36. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.90. Feedback's value of 0.36 is 96.7% below this industry median. Based on the distribution chart, Feedback ranks #7 out of 513 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Feedback's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Feedback ranks #7 out of 513 companies for EV-to-EBITDA. This places Feedback in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.90. Feedback's value of 0.36 is 96.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.90, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Feedback's current EV-to-EBITDA of 0.36 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Feedback. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feedback's current EV-to-EBITDA is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feedback stock overvalued right now?
Based on GuruFocus' analysis, Feedback (LSE:FDBK) is currently considered Possible Value Trap. The stock's GF Value™ is £0.12, compared to a current price of £0.06 — trading 49.6% below its estimated fair value. The current EV-to-EBITDA is 0.36 and 96.7% below the Healthcare Providers & Services industry median of 10.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Feedback (LSE:FDBK), the current EV-to-EBITDA is 0.36 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FDBK has been successfully added to your 
